ATE194496T1 - Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten - Google Patents

Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten

Info

Publication number
ATE194496T1
ATE194496T1 AT93919446T AT93919446T ATE194496T1 AT E194496 T1 ATE194496 T1 AT E194496T1 AT 93919446 T AT93919446 T AT 93919446T AT 93919446 T AT93919446 T AT 93919446T AT E194496 T1 ATE194496 T1 AT E194496T1
Authority
AT
Austria
Prior art keywords
pct
induction
microparticles
cellular responses
containing microparticles
Prior art date
Application number
AT93919446T
Other languages
English (en)
Inventor
Christine Gengoux
Claude Leclerc
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE194496T1 publication Critical patent/ATE194496T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93919446T 1992-09-11 1993-09-13 Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten ATE194496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9210879A FR2695563B1 (fr) 1992-09-11 1992-09-11 Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
PCT/FR1993/000876 WO1994006472A1 (fr) 1992-09-11 1993-09-13 Microparticules portant des antigenes et leur utilisation pour l'induction de reponses humorales ou cellulaires

Publications (1)

Publication Number Publication Date
ATE194496T1 true ATE194496T1 (de) 2000-07-15

Family

ID=9433435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93919446T ATE194496T1 (de) 1992-09-11 1993-09-13 Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten

Country Status (12)

Country Link
US (1) US5871747A (de)
EP (1) EP0662000B1 (de)
AT (1) ATE194496T1 (de)
AU (1) AU4966693A (de)
CA (1) CA2144425C (de)
DE (1) DE69329030T2 (de)
DK (1) DK0662000T3 (de)
ES (1) ES2149210T3 (de)
FR (1) FR2695563B1 (de)
GR (1) GR3034550T3 (de)
PT (1) PT662000E (de)
WO (1) WO1994006472A1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313975A1 (de) * 1993-04-28 1994-11-03 Cytech Biomedical Inc Immunisierungsmittel und Affinitätschromatographie-Trägermaterial
KR100372375B1 (ko) * 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
ES2108614B1 (es) * 1995-07-12 1998-07-16 Oncina Fco Javier Martin Vacunas polimerizadas.
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE235890T1 (de) * 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP0973873B1 (de) * 1997-04-08 2006-06-07 Pall Corporation Verfahren zur gewinnung von seltenen zellen aus blutprodukten
CA2297786C (en) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US6929907B2 (en) * 1999-12-31 2005-08-16 North Carolina State University Methods and compositions for determining the purity of chemically synthesized nucleic acids
AU2001255398A1 (en) * 2000-04-12 2001-10-30 Genetics Institute Inc. Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
MXPA03002643A (es) 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
JP4500540B2 (ja) * 2001-06-29 2010-07-14 ヴェリ‐キュー，インコーポレイテッド 化学的に合成された核酸の純度を決定し、かつ化学的に合成された核酸を精製するための方法および組成物
EP2280074A3 (de) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
EP1411770A4 (de) * 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
FR2828648A1 (fr) * 2001-08-16 2003-02-21 Adam Bouaziz Constitution d'un vaccin extractible a partir d'un insert immunogene.
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
EP1471887B1 (de) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
EP2283864A1 (de) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2338510A1 (de) 2002-07-19 2011-06-29 Novartis Pharma AG Impfstoffzusammensetzungen, die Amyloid-beta1-6 Antigen-Arrays enthalten
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
JP5557415B2 (ja) * 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
CA2553594A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (de) 2005-01-19 2011-10-12 Vaxinnate Corporation Zusammensetzungen mit Pathogen-assoziierten Molekularstrukturen und Antigene sowie ihre Verwendungen zur Stimulation einer Immunantwort
US20070081972A1 (en) * 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
CA2631704A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
CA2636139A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CA2683590A1 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2711021B1 (de) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Produkte und Verfahren zur Stimulation einer Immunantwort
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP3494966B1 (de) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immunmodifizierende partikel zur behandlung von entzündungen
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3303585A4 (de) 2015-06-03 2018-10-31 Board of Regents of the University of Nebraska Dna-editierung mit verwendung von einzelstrang-dna
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
JP2022552375A (ja) 2019-10-15 2022-12-15 コーネル・ユニバーシティー 遺伝子治療発現カセットからの発現レベルを調節するための方法
JP2023500793A (ja) 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
WO2021086973A2 (en) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
EP4065600A1 (de) 2019-11-25 2022-10-05 Cornell University Apoe-gentherapie
EP4138921A1 (de) 2020-04-23 2023-03-01 University Of Iowa Research Foundation Proteolytische gegen gp gerichtete chimären
WO2022040564A1 (en) 2020-08-21 2022-02-24 University Of Iowa Research Foundation Cationic nanoparticle adjuvants
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
WO2022125963A1 (en) 2020-12-11 2022-06-16 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
US20240238383A1 (en) 2021-05-21 2024-07-18 University Of Lowa Research Foundation Anti-oxidant containing particles and methods of use
US20240293322A1 (en) 2021-06-23 2024-09-05 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
WO2024197165A1 (en) 2023-03-21 2024-09-26 University Of Iowa Research Foundation Broad spectrum antifungal keto-alkyl-pyridinium compounds
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor
WO2025213111A2 (en) 2024-04-05 2025-10-09 Cornell University Aav expression of mirna to suppress human apoe mrna

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine

Also Published As

Publication number Publication date
US5871747A (en) 1999-02-16
CA2144425A1 (fr) 1994-03-31
GR3034550T3 (en) 2001-01-31
EP0662000B1 (de) 2000-07-12
ES2149210T3 (es) 2000-11-01
EP0662000A1 (de) 1995-07-12
FR2695563B1 (fr) 1994-12-02
DE69329030T2 (de) 2001-03-22
FR2695563A1 (fr) 1994-03-18
DK0662000T3 (da) 2000-11-13
WO1994006472A1 (fr) 1994-03-31
AU4966693A (en) 1994-04-12
CA2144425C (fr) 2008-12-30
DE69329030D1 (de) 2000-08-17
PT662000E (pt) 2000-12-29

Similar Documents

Publication Publication Date Title
ATE194496T1 (de) Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten
ATE163195T1 (de) Lösliche liganden für cd40
ATE47155T1 (de) Monoklonaler antikoerper.
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DE69626132D1 (de) Regulierung von essgewohnheiten
DE69632625D1 (de) Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
ATE166882T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
DK124087A (da) Immunogent peptidantigen svarende til plasmodium vivax circumsporozoitprotein
ATE267213T1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
TW272197B (de)
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DE69232483D1 (de) Mycobacteriumprotein und dessen verwendung
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification